Adaptive growth factor delivery from a polyelectrolyte coating promotes synergistic bone tissue repair and reconstruction

Traumatic wounds and congenital defects that require large-scale bone tissue repair have few successful clinical therapies, particularly for craniomaxillofacial defects. Although bioactive materials have demonstrated alternative approaches to tissue repair, an optimized materials system for reproducible, safe, and targeted repair remains elusive. We hypothesized that controlled, rapid bone formation in large, critical-size defects could be induced by simultaneously delivering multiple biological growth factors to the site of the wound. Here, we report an approach for bone repair using a polyelectrolye multilayer coating carrying as little as 200 ng of bone morphogenetic protein-2 and platelet-derived growth factor-BB that were eluted over readily adapted time scales to induce rapid bone repair. Based on electrostatic interactions between the polymer multilayers and growth factors alone, we sustained mitogenic and osteogenic signals with these growth factors in an easily tunable and controlled manner to direct endogenous cell function. To prove the role of this adaptive release system, we applied the polyelectrolyte coating on a well-studied biodegradable poly(lactic-co-glycolic acid) support membrane. The released growth factors directed cellular processes to induce bone repair in a critical-size rat calvaria model. The released growth factors promoted local bone formation that bridged a critical-size defect in the calvaria as early as 2 wk after implantation. Mature, mechanically competent bone regenerated the native calvaria form. Such an approach could be clinically useful and has significant benefits as a synthetic, off-the-shelf, cell-free option for bone tissue repair and restoration.National Institutes of Health (U.S.) (Grant R01 AG029601)National Institutes of Health (U.S.) (Grant R01 EB010246)National Institutes of Health (U.S.) (Grant P30 CA014051)Natural Sciences and Engineering Research Council of Canada (Fellowship

Nutrients and energy digestibility of microalgal biomass for fish feed applications

Aquafeed accounts for at least 75-90% of aquaculture's operating costs. Traditional aquafeed ingredients such as fishmeal, fish oil, and soybean meal are unsustainable; further, their increasing cost necessities developing alternative feed ingredients. Microalgae-based aquafeed is not only environmentally friendly, but it can also be cost-effective with proper optimization. In addition, the nutrition profile of microalgae is similar to that of many fishes. The digestibility of a feed is one of the most important factors to consider in feed formulation. A highly digestible feed can lower production costs, reduce feed waste, and reduce the risk of eutrophication. This review discusses the digestibility of various nutrients such as protein, lipid, carbohydrate, amino acids, and fatty acids (including omega-3 fatty acids), dry matter, and energy of various microalgae in fish. Other commonly used aquafeed ingredients were also compared to microalgae in terms of nutrient and energy digestibility in fish. The intrinsic characteristics of microalgae, biomass pretreatment, and feed preparation methods are all discussed as factors that contribute to the nutrient and energy digestibility of microalgae in fish. Furthermore, methods for increasing the digestibility of microalgal biomass in fish are suggested. Finally, the review concludes with the challenges and prospects of using microalgae as a fish feed in terms of digestibility. 2021 by the authors. Licensee MDPI, Basel, Switzerland.This research was funded by Qatar National Research Fund (QNRF, a member of Qatar Foundation), grant number MME01-0910-190028.Scopu

DRUG UTILIZATION STUDY OF ANTIPSYCHOTICS AND ITS COMMON ADR'S IN THE PSYCHIATRY OPD OF OHRC

Objective To determine the safety and efficacy of the drug used. To analyze drug utilization pattern. To identify the ADR's caused by psychotropic drugs Methods: IRB approval was obtained and a hospital based cross sectional study was carried out at psychiatric OPD of OHRC. 500 prescriptions were collected and information was recorded in data collection form and analyzed. Results: From 500 prescriptions, 46.8% of prescriptions were of males and 53.2% of prescriptions were of females. Schizophrenia accounted for 29.6% of prescriptions whereas, 38.4% were of mood disorder, 21.6% were of anxiety and 10.4% were of other disorders.Drug Utilization Pattern in different psychiatric disorders: Mood disorder was the most common diagnosis followed by schizophrenia and anxiety. In mood disorder, the most commonly prescribed drug was escitalopram and the least commonly prescribed drug was fluoxetine. In schizophrenia the most commonly prescribed drug was diazepam and the least commonly prescribed drug was aripiprazole. In anxiety, the most commonly prescribed drug was clonazepam and the least commonly prescribed drug was haloperidol. PDD/DDD ratio of escitalopram and sodium valproate was nearer to one. Conclusion: In this study we get to know about the current prescribing trend of the psychotropic drugs and we also came to know the corresponding ADR'S of the drugs prescribed

Microalgal Feedstock for Biofuel Production: Recent Advances, Challenges, and Future Perspective

Globally, nations are trying to address environmental issues such as global warming and climate change, along with the burden of declining fossil fuel reserves. Furthermore, countries aim to reach zero carbon emissions within the existing and rising global energy crisis. Therefore, bio-based alternative sustainable feedstocks are being explored for producing bioenergy. One such renewable energy resource is microalgae; these are photosynthetic microorganisms that grow on non-arable land, in extreme climatic conditions, and have the ability to thrive even in sea and wastewater. Microalgae have high photosynthetic efficiencies and biomass productivity compared to other terrestrial plants. Whole microalgae biomass or their extracted metabolites can be converted to various biofuels such as bioethanol, biodiesel, biocrude oil, pyrolytic bio-oil, biomethane, biohydrogen, and bio jet fuel. However, several challenges still exist before faster and broader commercial application of microalgae as a sustainable bioenergy feedstock for biofuel production. Selection of appropriate microalgal strains, development of biomass pre-concentrating techniques, and utilization of wet microalgal biomass for biofuel production, coupled with an integrated biorefinery approach for producing value-added products, could improve the environmental sustainability and economic viability of microalgal biofuel. This article will review the current status of research on microalgal biofuels and their future perspective. 2023 by the authors.This research was funded by Qatar National Research Fund grant number MME01-0910-190028.Scopu

A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin

Standard cell proliferation assays use bulk media drug concentration to ascertain the potency of chemotherapeutic drugs; however, the relevant quantity is clearly the amount of drug actually taken up by the cell. To address this discrepancy, we have developed a flow cytometric clonogenic assay to correlate the amount of drug in a single cell with the cell’s ability to proliferate using a cell tracing dye and doxorubicin, a naturally fluorescent chemotherapeutic drug. By varying doxorubicin concentration in the media, length of treatment time, and treatment with verapamil, an efflux pump inhibitor, we introduced 10[superscript 5]–10[superscript 10] doxorubicin molecules per cell; then used a dye-dilution assay to simultaneously assess the number of cell divisions. We find that a cell’s ability to proliferate is a surprisingly conserved function of the number of intracellular doxorubicin molecules, resulting in single-cell IC[subscript 50] values of 4–12 million intracellular doxorubicin molecules. The developed assay is a straightforward method for understanding a drug’s single-cell potency and can be used for any fluorescent or fluorescently labeled drug, including nanoparticles or antibody–drug conjugates.Hertz Foundation (Fellowship)National Science Foundation (U.S.). Graduate Research Fellowship ProgramPfizer Inc.National Cancer Institute (U.S.) (David H. Koch Institute for Integrative Cancer Research at MIT. Support (Core) Grant P30-CA14051